Bloomberg News

Teva Rises Most in Month on Lipitor Speculation, P&G Venture

November 04, 2011

(Updates with closing share prices in second paragraph, P&G deal in fifth, rating change in last.)

Nov. 3 (Bloomberg) -- Teva Pharmaceutical Industries Ltd. rose the most in more than a month on speculation it may start selling a generic of Pfizer Inc.’s Lipitor anti-cholesterol pill and as it formed a partnership with Procter & Gamble Co.

The shares of the world’s largest generic drugmaker climbed 5.2 percent, the biggest increase since Oct. 2, to 149.10 shekels, at the 4:30 p.m. close in Tel Aviv.

Teva said yesterday that if it manages to introduce an “important undisclosed product” in the fourth quarter, it would meet the upper range of its forecast of earnings excluding some costs of $4.92 to $5.02 a share this year.

“This is ostensibly Lipitor,” Sanford C. Bernstein & Co. analysts led by Ronny Gal wrote in a report late yesterday. “What other product can give Teva 10 cents of earnings per share or $89 million net income in one month?”

Separately, Teva and Procter & Gamble said a new consumer- health care partnership “has the potential to reach double- digit sales growth and $4 billion in sales towards end-of- decade.”

Also, Morgan Stanley raised its recommendation on Teva to “overweight” from “equal weight.”

--With assistance from Sharon Wrobel in Tel Aviv. Editors: Susan Lerner, Peter Branton

To contact the reporters on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net; Naomi Kresge in Berlin at nkresge@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net


Silicon Valley State of Mind
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus